A sensitive method for assay of a novel tricyclic compound using coulometric electrochemical detection.
A reversed-phase high-performance liquid chromatographic method using coulometric electrochemical detection in the oxidative mode has been developed for the analysis of 3-(9-chloro-5,6-dihydro-11-H-pyrrolo[2,1-b][3]benzazepine-11-ylidene- N,N-dimethyl-1-propanamine(E)-Z-butenedioate hydrogen maleate (1) in plasma of patients dosed with 2-8 mg/kg/d of the drug. Concentrations as little as 0.1 ng/mL of 1 in plasma can be estimated with a mean coefficient of variation of 7.4 +/- 1.08%. The utility of the procedure was demonstrated by the analysis of 500 patient samples from a rising multiple-dose study.
Fisher
A L
AL
Merck Sharp & Dohme Research Laboratories, West Point, PA 19846.
Bayne
W F
WF
Musson
D G
DG
D000929:Antidepressive Agents, Tricyclic / Q000032:analysis* / Q000097:blood; D001552:Benzazepines / Q000032:analysis* / Q000097:blood; D002851:Chromatography, High Pressure Liquid; D004563:Electrochemistry; D006801:Humans
D000929:Antidepressive Agents, Tricyclic; D001552:Benzazepines; C063029:3-(9-chloro-5,6-dihydro-11-H-pyrrolo(2,1-b))(3)benzazepine-11-ylidine-N,N-dimethyl-1-propanaminebutenedioate